Description
STRENSIQ® (asfotase alfa) is indicated for the treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP).
Additional information
| Brand | STRENSIQ® |
|---|---|
| Generic name | Asfotase alfa for injection |
| Form | Parenteral |
| Strength | 40mg/mL |
| Packing | 12 vials |
| Manufacturer | Alexion Pharmaceuticals |
| Documents | Either PO or prescription |
| Storage | 2-8°C temperature |
Reviews
There are no reviews yet.